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The Evaluation of Essential Oils for Antimicrobial Activity
Abstract
The emergence of antibiotic resistant bacteria is of pressing concern as health care
associated infections kill 99,000 people a year in the U.S. alone. Researchers are currently
looking for new antibiotics in alternative sources. Essential oils are traditionally known to have
medical benefits, and cinnamon, tea tree, and eucalyptus oils have shown antibiotic activity.
Initial testing via standard microbiological protocols found minimum inhibitory concentration
(MIC) values of 0.039% for cinnamon, 1.25% for tea tree, and 0.313% for eucalyptus. All three
oils proved effective against both Gram-positive and Gram-negative bacteria. Cinnamon bark
oil, Cinnamomum cassia Blume, appeared most effective. More thorough microbiological
analysis revealed it to be bactericidal and retained antibacterial activity in the presence of human
serum protein. The results revealed cinnamon bark oil may contain a promising novel antibiotic.

Introduction
Infectious diseases, particularly those caused by bacterial microorganisms, are still
among the top causes of mortality in the world. The rate of infections caused by bacteria that
have acquired antibiotic resistance is a staggering proportion. This is especially concerning in
hospital settings where 1.7 million health care-associated infections are acquired and kill 99,000
people every year. It is estimated that these infections cause between $28 and $32 billion dollars
to the health care industry (5). Several resistant strains, such as multi-antibiotic resistant
Staphylococcus aureus (MRSA), carbapenem resistant enterobacteriaceae (CRE), Vancomycin
Resistant Enterococci (VRE), and antibiotic resistant hypervariant Clostridium difficile (Cdiff),
are commonly acquired through a nosocomial infection and demonstrate the necessity of novel
antibiotics to combat bacteria that have become resistant to currently used antibiotics.
Bacteria can become resistant to antibiotics in a number of ways, one of which is random
mutation. Mutations can occur in DNA which would usually code for antibiotic sensitivity and
in turn code for resistance (9). Once this occurs, the bacterium can spread the mutation when it
produces daughter cells (9). This mutation occurs in about one per million to one per billion
cells (9). Another mode by which bacteria can become resistant is by the transfer of plasmids
that code for resistance from one cell to another through conjugation. For either circumstance,
once one bacterium becomes resistant, the number of resistant bacteria will begin to increase (9).
There has been much concern in recent years over the misuse and overuse of antibiotics. Misuse
can occur with the prescription of antibiotics when they are not necessary, and some worry
antibiotics are being overused in the agriculture and livestock business where recommended
doses are commonly added to feed for health purposes and increased rates of livestock growth
(9). When this occurs, resistant bacteria survive and are artificially selected for and allowed to
replicate. This can lead to rapid growth of resistant bacteria which are resistant to current
antibiotics. There are few treatments currently available that can combat these antibiotic
resistant bacteria, and the necessity of novel antibiotics is becoming evident.
Unfortunately, progress in the development of new antibiotics has tapered off as several
large pharmaceutical companies have decreased their infectious disease discovery programs.
Much of the current research is looking toward synthesizing novel derivatives which are
modeled after current antibiotics (11). There has been low success rates in finding novel
antibiotics with these derivatives, and this could be because a majority of the antibiotics used

today are produced naturally from soil streptomycetes and fungi (11). While many large
companies are focusing on manmade products, and finding little success, some researchers are
once again looking toward natural sources for new and improved antibiotics (11). One natural
product, which has been around for thousands of years, may hold the key to finding new
antibiotics: essential oils derived from plants.
EOs are aromatic liquids generally made through a steam distillation process of plant
material which can be traced back over 2000 years to Egyptian, Persian and Indian roots; but can
also be made through extraction, enfleurage, fermentation and expression (2). EOs are typically
made from aromatic plants of warm, tropical regions and can be made from nearly any plant
organ, such as leaves, bark, herbs, roots, seeds, stems, and fruits. Climate, soil, plant organ, age
of plant, and harvest time all affect the quality and quantity of an essential oil yield (1). EOs
have been used for pharmaceutical purposes since the 13th century in some areas of Europe (7),
but their use was not widespread until they were traded in London in the 16th century (2). French
physician, Du Chesne, noted that by the 17th century, EOs were a common medical practice in
Europe, with pharmacies stocking 15 to 20 different essential oils at a time (7). It was not until
1881 that EOs were tested for antimicrobial properties, when De La Croix examined vapors (2).
By the 19th and 20th centuries, EOs were increasingly used for fragrances and flavoring different
foods (7).
Today, only a small percentage of the essential oils created are used for aromatherapy.
EOs have countless uses, such as perfumes, cosmetics, dentistry, food preservatives and
flavoring, and more (1). In recent years, more research has been done to determine the
antimicrobial nature of numerous EOs against different bacteria (1, 7). Essential oils have also
been found to have antiviral, antiparasitic, insecticidal, antitoxigenic, antiseptic, and tumor
inhibiting activities as well (1, 2, 10). Because EOs are made from various plant components, it
stands to reason that they would contain properties that the plant uses to protect itself from
bacteria, viruses, and unwanted insects, while containing fragrances that could help attract
insects that would be beneficial for pollination (1). Studies show EOs have the potential to solve
a variety of different medical problems, including the crisis of antibiotic resistance of infectious
bacteria.
We initially tested several essential oils using the Agar Disk Diffusion Test, or the Zone
of Inhibition Test, to determine if the oil had any antibiotic activity. If an oil demonstrated a
promising zone, further testing for Minimum Inhibitory Concentrations (MICs) were performed
against Staphylococcus aureus and Escherichia coli. Cinnamon bark oil showed a very low
MIC, meaning that it remained effective in small doses, and was tested using a Time Kill
experiment to determine if it is bacteriostatic or bactericidal.

Methods
Essential Oils
The essential oils tested were from a variety of different brands. The following oils were
Plant Therapy brand: pine (Pinus Sylvestris), cinnamon bark (Cinnamomum cassia Blume),
spearmint (Mentha spicata), peppermint (Mentha piperita), and juniper berry (Juniperus
communis). Lavender (Lavandula officinalis) and ginger (Zingiber officianale) were Now

Essential Oils. Orange oil was of the brand LorAnn Oils. The tea tree (Melaleuca alternifela),
eucalyptus oils tested were Sundown Naturals and Aura Cacia, respectively.
Anthranilic Acid Derivative- GV-2
GV-2 was prepared by the Chemistry Department at GVSU and identified using
analytical (C, H, N) and spectral (IR, HNMR, CNMR, Mass) data. GV-2 shows antimicrobial
activity against Gram-positive bacteria, but is not effective against those that are Gram-negative.
GV-2 is used as a positive control against Staphylococcus aureus and a negative control against
Escherichia coli for this reason. GV-2 has an MIC value of 16.0 µg/mL against S. aureus, but this
value increases in the presence of Human Serum Protein to 128 µg/mL.

Zone Of Inhibition Test
Initial testing to determine antimicrobial activity of the test compounds was by the zone
of inhibition test, or agar disc diffusion method (4). The zone of inhibition test, begins by
swabbing a plate with overnight cultures of Staphylococcus aureus and Escherichia coli to create
a “lawn.” Five microliters of essential oil were pipetted onto 6 millimeter sterile paper disks
which were placed atop the bacterial “lawn” and incubated for 18-24 hours at 37oC. Areas of
clearing, or zones of inhibition, around the disks after incubation are measured and indicate that
the compound has some antimicrobial activity. Diameter of zones of inhibition were measured
in millimeters and recorded.
Determination of MIC
The MIC’s of the tested essential oils were determined by the Clinical Laboratory
Standards Institute’s method of broth microdilution (3). The MIC’s were determined by
inoculation of serial dilutions of the essential oil being tested in Mueller-Hinton broth with S.
aureus or E. coli. Cultures were incubated at 37oC for 18-24 hours. If appropriate, 100% Human
Serum was added to a final concentration of 10%.
Time Kill
The Time Kill Assay performed on Cinnamon Oil used a solution of four or eight times
the MIC of the essential oil. The solution contained final concentrations of 10% test compound,
80% Mueller-Hinton broth, and 10% inoculum. Inoculum was created by diluting a 0.5
Macfarland 1:20. Growth controls of 9.68% and 4.84% DMSO were utilized to mimic the
DMSO concentrations in the Cinnamon 8X and 4X tubes, respectively. Solutions are allowed to
incubate for 24 hours with one hundred microliter samples taken initially (0 hours), and at 3, 6,
and 24 hours after inoculation. Samples are serially diluted and plated in duplicate to determine
the number of colony-forming-units per mL (CFU/mL) at the given sample time.

Results and Discussion
Initial testing of the EOs using the agar disk diffusion method resulted in zones of
clearance, or no growth, listed in table 1. Cinnamon bark and eucalyptus had the largest zones
on S. aureus with zones of 27.5 and 19.5 mm, respectively, and were comparable to our positive
control, GV-2, which measured 26.2 mm in diameter. Peppermint and spearmint also had large

zones against S. aureus, 19.5 and 28.0 mm respectively. They were not subjected to further
testing because of the growth of mutant colonies within the zone of clearance, peppermint on E.
coli and spearmint on S. aureus (data not shown). The presence of mutant colony growth
suggests that it is fairly easy for S. aureus or E. coli to resist either peppermint or spearmint, and
thus there was no further interest in the two EOs as antibiotics.
MIC values against S. aureus were determined for cinnamon bark, eucalyptus, and tea
tree oils; 0.04%, 0.31%, and 1.25% respectively (table 1). GV-2 has an MIC against S. aureus of
16.0 µg/mL, but this value increases to 128.0 µg/mL in the presence of 10% Human Serum
Protein (HSP). Since cinnamon bark oil had the lowest MIC, we tested its activity in the
presence of HSP, and it retained the MIC of 0.04%. GV-2, as well as numerous other
compounds, bind to HSP, and thus more of the compound must be used in order to inhibit
bacterial growth. Binding to HSP can cause concern when considering these compounds as
medication because the desired effective concentration is very low, as it will be less toxic to the
body. Because cinnamon bark oil retains its MIC in the presence of HSP, lower concentrations
could be used for medicinal purposes when it could be subjected to HSP in the bloodstream.
Chemical
Name

Zone of
Inhibition
on
S. aureus
(mm)

Zone of
Inhibition
on E. coli
(mm)

MIC
against
S. aureus

MIC against
S. aureus with
10% Human
Serum Protein

MIC
against
E. coli

MIC against
E. coli with
10% Human
Serum
Protein

Cinnamon
Bark
Eucalyptus
Tea Tree
GV-2
Peppermint

27.5

12.5

0.04%

0.04%

0.04%

0.04%

19.5
13.7
26.2
19.5

15.5
15.7
0.0
8.7

0.31%
1.25%
16.0 µg/mL
---

----128.0 µg/mL
---

0.31%
-------

---------

Pine

6.7

7.2

---

---

---

---

Lavender

13.0

8.0

---

---

---

---

Spearmint

28.0

9.0

---

---

---

---

Ginger

9.5

0.0

---

---

---

---

Juniper
Berry

14.5

0.0

---

---

---

---

Table 1. Zone of Inhibition (diameter), and MIC values (percentage of oil and µg/mL for GV-2) of several essential
oils and synthesized compounds. Dashes indicate no testing of the compounds.

A time kill assay was performed to determine if cinnamon bark oil kills bacteria or
inhibits its growth. The values of table 2, reported in log10 Colony Forming Units (CFU) per
milliliter, depict the increase of bacterial growth that would be expected at each of the sampling
times. The concentrations of the growth control, 9.68% and 4.84% DMSO, match those of the
cinnamon ark Oil at 8X and 4X the MIC. This allows for better comparison of growth between
the control and the cinnamon bark oil. The growth control also depicts that DMSO is not
responsible for the decrease in bacteria after incubation as the CFU/mL increases over time. A 3
log10 decrease or greater in bacteria when subtracting the count at 0 hours from 24 hours

constitutes the test compound as bactericidal (14). If the difference is less than a 3 log10, this
suggests bacteriostatic (14). According to the summarized results of the time kill (table 3), GV2, a known bacteriostatic compound, registered a 0.4 log10 and 2.7 log10 decrease in CFU/mL for
4X and 8X times the MIC, respectively, which falls in the given parameter to be determined
bacteriostatic.
Cinnamon bark oil had a 3.6 log10 decrease in bacteria at a concentration of 4X the MIC
after 24 hours of incubation. The results for 8X the MIC are recorded as ND in tables 2 and 3
because there was no growth detected from undiluted samples. This indicates that the cinnamon
bark oil killed such a great number of bacteria that they were virtually undetectable at the 3, 6
and 24 hour tubes, when the results for other concentrations and compounds needed to be diluted
in order to be counted. Because there was no growth, no proper log10 value could be associated
with the sample, yet these results conclude that the cinnamon bark oil is bactericidal. The
experiment was repeated with only cinnamon at 8X the MIC, and the results were consistent with
the original experiment.
Time Point
(hours)

0
3
6
24

Growth
Control
9.68%
DMSO
5.4
6.2
7.0
8.8

Growth
Control
4.84%
DMSO
5.7
6.6
7.8
8.9

Cinnamon
Bark Oil
8X MIC
0.32%
5.4
ND
ND
ND

Cinnamon
Bark Oil
4X MIC
0.16%
5.6
4.7
4.1
2

GV-2
8X MIC
128 µg/mL

GV-2
4X MIC
64 µg/mL

5.7
4.9
4.9
3.0

5.6
5.2
5.3
5.2

Table 2. Time Kill Experiment summary of the antibacterial activity of cinnamon bark oil and a comparator agent
(GV-2) versus Staphylococcus aureus. Results shown are reported as log10 colony forming units (CFU) per
milliliter. Samples were taken at 0, 3, 6, and 24 hours to determine the CFU in solution at each time point. A result
of “ND” indicates that there was no detectable growth from the sample.

Antibacterial Agent
Cinnamon Bark Oil
Cinnamon Bark Oil
GV-2
GV-2

Concentration (FoldMIC)
0.32% (8X)
0.16% (4X)
128.0 µg/mL (8X)
64.0 µg/mL (4X)

Maximal kill at any
time point
ND
-3.6
-2.7
-0.4

Bacterial kill at 24
hours
ND
-3.6
-2.7
-0.4

Table 3. Summarized Time-kill results for cinnamon bark oil and GV-2. Maximal Kill and Kill after 24 hours
determined by Bacterial count after incubation minus the initial inoculum. A negative value indicates a net kill and
a positive value indicates a net growth. Results of the time kill are reported as log10 CFU/mL. A result of “ND”
indicates that there was no detectable growth from the sample.

Having a bactericidal quality can be useful when understanding how a compound
interacts with the bacteria it is targeting. Because it is killing bacteria, there may be some
concern that cinnamon bark oil could have some toxic effect for human cells. Cinnamon bark oil
has been used for years to add flavor, and as a health preventative measure for different types of
animals, such as lactating sows and small piglets, indicating that it does not appear to be toxic in
minimal doses (2). Cytotoxicity tests have been run on various cinnamon oils, including
Cinnamomum zeylancium (6, 13), and Cinnamomum cassia Blume. Fabio et al. tested the

cytotoxicity of several essential oils, and could not determine if cinnamon oil’s (Cinnamomum
zeylancium) antimicrobial activity was due to cytotoxicity, as the MIC was higher than the
highest minimum nontoxic concentration (6). On the other hand, Ooi et al. concluded that
Cinnamomum zeylancium inhibited cell growth of rat fibroblast cells in a concentration
dependent matter, but did not show cytotoxicity in a time dependent-matter (13).
While it may not be logical to distribute cinnamon bark oil as an antibiotic, one of its
constituents may have antibacterial properties from which an antibiotic could be derived.
Researchers have determined that cinnamon bark oil (Cinnamomum cassia Blume) is largely
composed of trans-cinnamaldehyde, approximately 85%, and nearly 9% o-methoxycinnamaldehyde (12). When comparing the microbial activity of cinnamon bark oil to its major
component, cinnamaldehyde, results showed nearly the same activity for both (12). As
cinnamon bark oil showed promising results in the Zone and MIC tests, one next step in research
may be to investigate the individual components of the oil for antimicrobial activity. Further
testing on trans-cinnamaldehyde and o-methoxy-cinnamaldehyde of Cinnamomum cassia Blume
(12) and Cinnamomum zelanicum, (7); and cinnmyl cinnamate, and benzyl cinnamate of
Cinnamomum zelanicum (7) to determine MICs and cytotoxicity are worthwhile in the pursuit of
novel antibiotics.
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